BioCentury on BioBusiness,
Politics and Policy
NIH patent decision pushes HGSI stock down
Monday, February 14, 1994
NIH patent decision pushes
HGSI stock down
Human Genome Sciences Inc. shares fell $2.75 to $16.25 on Friday, reflecting Wall
Street's concerns about the impact of a government decision to give up on patenting human
HGSI was formed to exploit precisely the kind of partial cDNA sequences involved in the
decision, which it creates using its automated gene sequencing technology. In the
prospectus for its initial public offering last December, the Rockville, Md., company said
there is "substantial uncertainty regarding the patentability of genes based on
partial sequences." HGSI also said it planned to file for patents for genes when they
were partially sequenced and subsequently if they
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]